Brittany B. Lundy

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
The therapeutic potential of RNA interference (RNAi) has been limited by inefficient delivery of short interfering RNA (siRNA). Tumor-specific recognition can be effectively achieved by antibodies directed against highly expressed cancer cell surface receptors. We investigated the utility of linking an internalizing streptavidin-conjugated HER2 antibody to(More)
  • 1